Denmark's Bavarian Nordic prelim 2025 revenue beats on vaccine demand

Bavarian Nordic A/S

12/02/2026 06:52

Overview

Denmark vaccine firm's preliminary 2025 revenue beat analyst expectations

Preliminary EBITDA margin for 2025 exceeded company's own guidance, driven by strong vaccine demand

Company expects normalized Public Preparedness revenue and growth in Travel Health for 2026

Outlook

Bavarian Nordic expects 2026 revenue of DKK 5,000 – 5,200 million

Company anticipates 10% growth in Travel Health revenue excluding partnerships

Public Preparedness revenue expected to normalize at DKK 1,800 – 2,000 million

Result Drivers

TRAVEL HEALTH GROWTH - Strong demand for rabies and TBE vaccines, along with the launch of the chikungunya vaccine, drove a 30% increase in Travel Health revenue

PUBLIC PREPAREDNESS DEMAND - Surge in demand for mpox vaccines led to Public Preparedness revenue exceeding normal levels by over DKK 1,000 million

PRIORITY REVIEW VOUCHER - Sale of Priority Review Voucher contributed DKK 810 million to other net operating income, boosting EBITDA margin

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Beat
DKK 6.24 bln
DKK 6.03 bln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Bavarian Nordic A/S is DKK250.00, about 33.5% above its February 11 closing price of DKK187.30

Press Release: ID:nGNE4DSNmz

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)